Science & health
First human trial begins for an siRNA treatment targeting prion disease
A phase 1 trial is enrolling 15 symptomatic prion-disease patients to test an siRNA drug designed to reduce production of the misfolded prion protein that drives these fatal neurodegenerative disorders. The study will assess safety, tolerability and dosing before any larger efficacy trial. Animal work found that a single dose lowered prion protein in mice and extended survival after symptoms began, but those results do not show the treatment will work in people. The researchers have committed to publicly sharing trial findings.
Editorial summary · Publisher article
What matters
- The candidate is a divalent siRNA, linking two molecules to distribute more broadly in the brain.
- The PRiSM study is enrolling patients who already show symptoms and is designed as an initial safety and mechanism study.
- In mice, the treatment lowered prion protein by 49% and increased survival time by 64% after symptom onset.
- The trial is supported by NIH’s NeuroNEXT program, with additional development funding from NIH grants and community donations.
From animal results to human testing
The treatment’s rationale comes from earlier work showing that lowering prion-protein levels can delay disease onset and slow progression in animals. The human trial is the first test of whether the approach is safe and active in patients.
Context & caveats
- Animal survival results are preliminary evidence, not proof of clinical benefit; the phase 1 trial may determine safety without showing efficacy.
Why this made the edition
Strong primary-source health reporting gives concrete trial design, mechanism, prior animal results, funding and the essential limitation that this first-in-human phase 1 study is intended to assess safety and dosing, not establish efficacy.
Source material